Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Carcinoma, Renal Cell 26Sarcoma 16Neoplasm Metastasis 12Carcinoma, Non-Small-Cell Lung 9Ovarian Neoplasms 8Breast Neoplasms 8Recurrence 6Neoplasms 5Melanoma 4Liposarcoma 4Leiomyosarcoma 4Glioblastoma 4Fallopian Tube Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Neuroendocrine Tumors 3Lung Neoplasms 3Kidney Neoplasms 3Hemangiosarcoma 3Gastrointestinal Stromal Tumors 3Thyroid Neoplasms 2Thyroid Carcinoma, Anaplastic 2Sarcoma, Synovial 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2Pancreatic Neoplasms 2Osteosarcoma 2Gliosarcoma 2

Interventions

Gemcitabine 2Docetaxel 2pegfilgrastim 1pazopanib 1ixabepilone 1Thalidomide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recurrent Uterine Corpus Sarcoma × pazopanib × Clear all
NCT01247571 2019-08-08

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
22 enrolled 8 charts
GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡